KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Assets (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Assets for 16 consecutive years, with $5.0 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Assets rose 17.13% year-over-year to $5.0 billion, compared with a TTM value of $5.0 billion through Dec 2025, up 17.13%, and an annual FY2025 reading of $5.0 billion, up 17.13% over the prior year.
  • Assets was $5.0 billion for Q4 2025 at Alnylam Pharmaceuticals, up from $4.9 billion in the prior quarter.
  • Across five years, Assets topped out at $5.0 billion in Q4 2025 and bottomed at $3.3 billion in Q1 2021.
  • Average Assets over 5 years is $3.9 billion, with a median of $3.7 billion recorded in 2021.
  • The sharpest move saw Assets surged 42.8% in 2021, then decreased 5.1% in 2022.
  • Year by year, Assets stood at $3.6 billion in 2021, then decreased by 2.66% to $3.5 billion in 2022, then increased by 7.99% to $3.8 billion in 2023, then rose by 10.71% to $4.2 billion in 2024, then rose by 17.13% to $5.0 billion in 2025.
  • Business Quant data shows Assets for ALNY at $5.0 billion in Q4 2025, $4.9 billion in Q3 2025, and $4.6 billion in Q2 2025.